Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29159126 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL12610926 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL838670 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL12024467 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL6389608 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL1527311 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL14367329 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL18543456 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL542034 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL838671 | 1.00 | ALDH1A1 (0.39) | ALDH1A1EPHX2SIGMAR1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | claimed |
| US-5440062-A | One-(substituted)amino-7-(substituted)imino-1,3,5-cycloheptatriene-metal complexes as catalysts | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-08-08 | — | — | US | claimed |
| WO-1989010916-A1 | ENANTIOSELECTIVE ADDITION OF HYDROCARBONS TO ALPHA,BETA-UNSATURATED CARBONYL COMPOUNDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-11-16 | — | — | WO | claimed |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | ASKAT INC. (JP) | 2023-01-17 | — | — | US | disclosed |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| US-5440062-A | One-(substituted)amino-7-(substituted)imino-1,3,5-cycloheptatriene-metal complexes as catalysts | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-08-08 | — | — | US | disclosed |
| US-5162586-A | Catalyst complex containing copper, a disubstituted aminetroponeimine chelating ligand and an organometallic reagent | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1989010916-A1 | ENANTIOSELECTIVE ADDITION OF HYDROCARBONS TO ALPHA,BETA-UNSATURATED CARBONYL COMPOUNDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2651/4885EPHX2 3254/4885SIGMAR1 3638/4885 |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | UACA, SLC7A1, CDYL | ALDH1A1 630/4885EPHX2 235/4885SIGMAR1 2292/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2460/4885EPHX2 3625/4885SIGMAR1 3665/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2651/4885EPHX2 3254/4885SIGMAR1 3638/4885 |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | UACA, SLC7A1, CDYL | ALDH1A1 630/4885EPHX2 235/4885SIGMAR1 2292/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | ALDH1A1 3404/4885EPHX2 3599/4885SIGMAR1 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.